Genome-wide association analysis identified splicing single nucleotide polymorphism in CFLAR predictive of triptolide chemo-sensitivity

Chauhan et al.
Genome-wide association analysis identified splicing single nucleotide polymorphism in CFLAR predictive of triptolide chemo-sensitivity

Lata Chauhan 1, Gregory D. Jenkins 2, Neha Bhise 3, Tanya Feldberg 3, Taraswi Mitra-Ghosh 3, Brooke L. Fridley 4 and Jatinder K. Lamba 1*

Abstract

Background: Triptolide is a therapeutic diterpenoid derived from the Chinese herb *Tripterygium wilfordii* Hook f. Triptolide has been shown to induce apoptosis by activation of pro-apoptotic proteins, inhibiting NFκB and c-KIT pathways, suppressing the Jak2 transcription, activating MAPK8/JNK signaling and modulating the heat shock responses.

Results: In the present study, we used lymphoblast cell lines (LCLs) derived from 55 unrelated Caucasian subjects to identify genetic markers predictive of cellular sensitivity to triptolide using genome wide association study. Our results identified SNPs on chromosome 2 associated with triptolide IC50 (p < 0.0001). This region included biologically interesting genes as CFLAR, PPIl3, Caspase 8/10, NFkB and STAT6. Identification of a splicing-SNP rs10190751, which regulates CFLAR alternatively spliced isoforms predictive of the triptolide cytotoxicity suggests its role in triptolides action. Our results from functional studies in Panc-1 cell lines further demonstrate potential role of CFLAR in triptolide toxicity. Analysis of gene-expression with cytotoxicity identified JAK1 expression to be a significant predictor of triptolide sensitivity.

Conclusions: Overall out results identified genetic factors associated with triptolide chemo-sensitivity thereby opening up opportunities to better understand its mechanism of action as well as utilize these biomarkers to predict therapeutic response in patients.

Keywords: Triptolide, Genome-wide association studies, Hap-map, Single nucleotide polymorphisms, CFLAR

Background

Triptolide is a biological diterpenoid derived from the Chinese herb *Tripterygium wilfordii* HOOK f. Triptolide has been shown to have anti-inflammatory and immunosuppressive activities and has been used in traditional Chinese medicine to treat several diseases, such as, rheumatoid arthritis, immune complex diseases, and systemic lupus erythematosus [1, 2]. It has been shown to have influence on several anti-tumor target genes and inhibit tumors by altering multiple signaling pathways, such as, inhibition of NFκB and c-KIT pathway [3], inhibition of Jak2 transcription [4], inducing apoptotic signals by activation of pro-apoptotic proteins [5, 6], activation of MAPK8/JNK [5, 6], and inhibition of heat shock response [7, 8]. Triptolide has also been shown to influence epigenetic modulation of genes by interaction with histone methyltransferase and demethylase [9]. In spite of the wide therapeutic properties of triptolide, poor water solubility has limited its clinical use in the past. However, recently a water-soluble analog of triptolide – Minnelide has shown promising results in pancreatic cancer cell lines, human xenograft models, as well as in mouse models of pancreatic cancer [10]. Minnelide has been shown to reduce tumor burden in preclinical models of osteosarcoma [11]. Taken together with the anti-tumor properties of triptolide and the recent development of triptolide analogs to overcome its water
solubility, triptolide has emerged as a promising anti-tumor agent.

In the present study, we evaluated the impact of genetic variations and gene expression profiles predictive of triptolide cytotoxicity using Epstein-Barr-virus transformed lymphoblastoid cell lines (LCLs) that are part of International HapMap project (www.hapMap.org) [12]. HapMap LCLs has been used as model to identify genetic markers associated with in vitro chemosensitivity to several drugs [13–16]. Genotype data is publically available allowing for genome-wide association analyses for biomarker identification. Our results validated some of the known genes/pathways as well as identified novel candidate genes/pathways of relevance to triptolide. We further validated the functional significance of CFLAR in pancreatic cell lines.

Methods
In vitro cytotoxicity assays
HapMap LCLs from subjects with European ancestry (CEU; n = 55 unrelated) were obtained from the Coriell Institute for Medical Research and were maintained as recommended. In vitro cytotoxicity was determined by treating LCLs with varying concentrations of triptolide (500, 50, 20, 10, 6.67, 1.3 and 0 nM) for 48 hr followed by cell viability measurements using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays (Life Technologies, USA) and Synergy 5 multi-plate reader. Cytotoxicity assays were performed in duplicates and cell lines were randomly chosen to repeat on different dates to rule out any experimental variation. Panc-1, a pancreatic cell line (ATCC, USA) was used for functional validation of the top gene identified in the GWAS. Panc-1 was cultured in DMEM medium supplemented with 2 mM glutamine and 10 % fetal bovine serum.

Real-time quantitative PCR analysis
mRNA expression levels of CFLAR spliced isoforms were quantitated in LCLs and Panc-1 cell lines using CFLAR isoform specific oligonucleotide primers and \(2^{-\Delta\Delta CT} \) method as described in Additional file 1 and Fig. 2.

Genotyping of panc-1 cell lines
Genomic DNA from Panc-1 cell line was genotyped for CFLAR SNP rs10190751 (A/G) using TaqMan SNP genotyping assay (Applied Biosystems, Foster City, CA, USA). Genomic DNAs from HapMap cell lines with known genotype (AA, AG and GG) were used as controls.

Western blotting
Western plotting was performed using whole-cell lysates and CFLAR (Enzo lifesciences) or β-actin (Abcam) primary and mouse IgG secondary antibodies.

siRNA mediated knockdown of CFLAR in cancer cell lines
Mission esiRNA were procured from Sigma Aldrich. esiRNA were synthesized through in vitro transcription of a 300–600 bp gene specific dsRNA, which is further digested in to complex pool of siRNA using RNAses. This digested pools of esiRNA are verified by DNA sequencing and gel electrophoresis to ensure identity and high specificity (Sigma Aldrich). To ensure high specificity and efficacy of the esiRNA, the algorithm DEQOR is utilized (Design and Quality Control of RNAi, available to the public via http://deqor.mpib-berlin.mpg.de/deqor_new/input.html). CFLAR specific 424 base pair sequence used in this study to create esiRNA pool for CFLAR knockdown is “TCCATCAGGTTGAAGAAGCACTTG ATA CAGATGAGAAGGAGATGCTGCTTTTTTGTGCCC GGGATGTGCTATAGATGTTGTCCACCTAATGTC TACAGACTCCTGCATATTATTTAGGAAGAGGTT AACCGCTGCTGCTCGGGACCTTTGCCAGCTGACTGCT CTCAGAGTGGGGGGTTTGGCTCTCAACAGTA TCTTGAAGATGACAGAAAGCTGTGGAGACCC ACTCTGCTCAGGAAACCTCACCCTTGTTCTCGGACT ATAGATGCTGTGCTGGCAGAGATGTGGTGAGATT TGGATAAAAATCTGATGTGGCTCTCATTTTCTTCT CATGAAGGATTACATGGGCGAGCAAGTAAGC AAGGAGAAGGTCTCTGGACCTTGTGTTGAGGT TGGAGAAAATCCTGTTGCGCCAGA”. Panc-1 cells were transfected with 200 nM CFLAR-esiRNA and negative siRNA using Lipofectamine® 2000 (Life technologies) as per manufacturer’s protocol. Twenty-four hours post-transfections cell were treated with varying concentrations of triptolide and cell viability was determined 48 hr post-treatment using MTT assays. mRNA levels of all three isoforms of CFLAR siRNA were quantitated 24 hr post-transfection to check for the knockdown.

Transfection of CFLAR-Short and CFLAR-Long plasmid in Panc-1 cell line
Panc-1 cells were transfected with control and CFLAR expression plasmids (pEF-Flag A, pEF-Flag A-CFLAR-S and pEF-Flag A-CFLAR-L) using Fugene HD reagent (Promega) followed by triptolide treatment and MTT assay as described above. Cell pellets were also collected for protein analysis.

Statistical analysis
As these cell lines are part of several publically available genotyping databases, genotype data was retrieved on all cell lines from the HapMap project (release 23). For 29 samples, data was also retrieved from the 1000 genomes project (20101123 version). mRNA expression was retrieved for all of the individuals from a publically available source (http://www.sanger.ac.uk/research/areas/humangenetics/). IC50 concentration that kills 50 % of the
cells, was calculated from a 4-parameter logistic model using the package drc v2.2.1 in R v2.14.0 [17].

**Association analysis of triptolide cytotoxicity with genetic variation**

SNP genotype (n = 4098136) data was retrieved from the HapMap (release 23) for all 55 samples (29 female and 26 male). SNPs were filtered using various quality control criteria as, build changes, call rate, compliance with Hardy Weinberg and minimum allele frequency (MAF) as described in Additional file 1. In total 1978803 SNPs in 55 individuals passed quality control measures. For genotype data for individuals in the 1000 genomes only a MAF filter was used, dropping SNPs with MAF < 0.05. Several SNPs overlap between the 1000 genomes and HapMap data, data obtained from the 1000 genomes project was used preferentially over data obtained from the HapMap. Since not all of the samples used have been sequenced as part of the 1000 genomes project as of current, SNPs in the 1000 genomes project, but not in HapMap (release 23) were imputed for samples not included in the 1000 genomes project. BEAGLE v3.3.1 [18] was used to impute SNPs with the reference of the 1000 genomes as described in Additional file 1.

**Association analysis of triptolide cytotoxicity with gene expression variation**

mRNA expression from the Illumina Sentrix Human-6 Expression BeadChip version 1 was normalized as per Stranger et al., using 47293 probes [19]. For this analysis, only the Caucasian samples were used and data was normalized using quantile normalization across replicates and median normalization across individuals. Original Illumina annotation was retrieved from ReMOAT [20]. Expression was not adjusted for gender (did not appear to affect association with phenotypes).

**Integrative analyses**

With the wealth of data produced by current genomic technologies, collection of multiple types of genomic data on a set of samples is becoming commonplace. New methods explore a multifactor approach that combine different kinds of genomic data, sometimes referred to as “integrative genomics” or “genomic convergence”, in which a multistep procedure is used to identify potential key drivers of complex traits that integrate DNA variation and gene expression data. To integrate the genotype, expression and drug cytotoxicity data, we first identified markers associated with triptolide IC$_{50}$ using a liberal significance threshold of 0.001. Next, we determined which expression probe sets were associated with triptolide IC$_{50}$ using a liberal significance threshold of 0.001. Finally, to determine whether the expression probe sets associated with these SNPs were also associated with triptolide IC$_{50}$ values, we identified which expression probe sets were associated with IC$_{50}$ with a $p$-values $\leq 0.0001$. A similar integrative analysis approach has been used successfully to detect novel candidate genes [21]. The association between IC$_{50}$ and SNP genotypes modeled as count of rare alleles (additive genetic model), or log$_{e}$ normalized mRNA expression and cytotoxicity phenotypes, or SNPs was quantified using a spearman correlation coefficient, and $p$-value calculated for the null hypothesis of no association using an F-test.

**Results**

**Genetic associations with triptolide IC$_{50}$ in LCLs**

We evaluated 55 LCLs derived from unrelated subjects with Caucasian ancestry for cellular sensitivity to triptolide. Triptolide IC$_{50}$ values ranged from 4 to 34 nM indicating wide inter-individual variation in chemosensitivity. GWAS analysis identified 140 SNPs in 11 genes that were associated with triptolide IC$_{50}$ at $p < 10^{-5}$ (488 SNPs at $p < 10^{-4}$; Fig. 1a). Significant proportion of SNPs (110 of 140: 78.6 %) clustered in ~293 kb region on chromosome 2 (Table 1), which maps to multiple biologically interesting genes (Genes important for cell division and Cancer development) including CFLAR, CLK1, FAM126B, NDUFB3, NIP3L1, ORC2 and PPIL 3 (Table 2; Fig. 1b). Other genes with significant SNPs included TP53BP2 (chr 1), MTSU2 (chr 13), ZNF532 (chr18) and FNDC3B (chr 3). Ingenuity pathway analysis of these genes mapped them to 4 networks (Table 3). These networks are involved in Cellular Movement, Inflammatory Response, Cell-To-Cell Signaling and Interaction; Cell Death and Survival, Cellular Function and Maintenance, Molecular Transport; Cancer, Dermatological Diseases and Conditions, Developmental Disorder; Cellular Movement, Hematological System Development and Function, Immune Cell Trafficking and carbohydrate metabolism.

CFLAR (Caspase 8 and FADD like apoptosis regulator) with maximum number of most significant SNPs (n = 41; due to high LD as shown in Additional file 2: Figure S1) was used successfully to detect novel candidate genes [21]. Some of the biologically interesting genes with expression levels associated with triptolide sensitivity included: JAK1 (Janus kinase 1), DTX1 (Deltex Homolog 1; positive regulator of Notch signaling pathway), AGL (Amylo-Alpha-1, 6-Glucosidase, 4-Alpha-Glucanotransferase involved in glycogen degradation), and MUC15 (Mucin 15, Cell
Surface Associated). Pathway analysis using Ingenuity pathway analysis tool mapped these genes to JAK/STAT, IL, iNOS, EGF signaling pathways (Additional file 4: Figure S3).

**Integrated SNP-mRNA association analysis with IC₅₀**

We performed integrated analysis between SNPs-mRNA expression-IC₅₀ we selected top SNPs that were significantly (p < 0.001) associated with cytotoxicity, and top gene expression signatures significantly (p < 0.001) associated with cytotoxicity for association with each other i.e. SNP vs. gene expression. This analysis basically identified eQTLs associated with triptolide IC₅₀ and at p < 0.0001 we identified 648 unique SNP-mRNA pairs that were associated with triptolide cytotoxicity however these SNP-mRNA pairs mapped to only 28 genes (Table 5), indicating association of multiple SNPs with one gene (which might be due to LD between SNPs). Some of the biologically interesting SNP-mRNA pairs included: association of multiple SNPs in chromosome 16 spanning genes CHST5, TMEM231, GABARAPL2 and ADAT1 with expression levels of AGL; SNPs in ASXL3 with ASCL4 expression; CAMTA1 SNPs and CRYGS expression; TIAM1 SNPs with DTX1 expression; SNPs in
Table 1: List of top 140 SNPs (p < 0.00001) from GWAS analysis that were predictive of triptolide cytotoxicity in HapMap LCLs

| SNP              | Position | Minor Allele | MAF | rIC50 | p value  | Chr | Gene_function_list                        |
|------------------|----------|--------------|-----|-------|----------|-----|------------------------------------------|
| rs6759004        | 202004676| C            | 0.15| −0.63 | 2.51E-07 | 2   | CFLAR/intron                            |
| rs10931931       | 201994540| C            | 0.15| −0.62 | 3.66E-07 | 2   | CFLAR/UTR-5                             |
| rs13413479       | 202012578| G            | 0.15| −0.62 | 3.66E-07 | 2   | CFLAR/intron                            |
| rs73045343       | 202017408| G            | 0.15| −0.62 | 3.66E-07 | 2   | CFLAR/intron                            |
| rs6712963        | 201982693| G            | 0.15| −0.62 | 3.78E-07 | 2   | CFLAR/intron                            |
| rs10469755       | 201917938| T            | 0.17| −0.62 | 4.43E-07 | 2   | CFLAR/intron                            |
| rs13059218       | 26910495 | A            | 0.24| 0.62  | 5.11E-07 | 3   |                                         |
| rs73045306       | 202000395| C            | 0.17| −0.61 | 6.01E-07 | 2   | CFLAR/intron                            |
| rs6759216        | 202004710| G            | 0.17| −0.61 | 6.01E-07 | 2   | CFLAR/intron                            |
| rs10203550       | 202009586| G            | 0.17| −0.61 | 6.01E-07 | 2   | CFLAR/intron                            |
| rs13426823       | 202016245| A            | 0.17| −0.61 | 6.01E-07 | 2   | CFLAR/intron                            |
| rs73045341       | 202016550| G            | 0.17| −0.61 | 6.01E-07 | 2   | CFLAR/intron                            |
| rs111315781      | 201738724| T            | 0.14| −0.61 | 6.27E-07 | 2   | PPL3/Intron                             |
| rs73439953       | 56602702 | T            | 0.33| −0.61 | 7.51E-07 | 18  | ZNF532/intron                           |
| c2.201734921.b37p0| 201734921| G            | 0.14| −0.61 | 9.19E-07 | 2   |                                         |
| rs55953858       | 201997292| G            | 0.21| −0.60 | 1.66E-06 | 2   | CFLAR/intron                            |
| rs4035022        | 201744352| A            | 0.15| −0.59 | 1.76E-06 | 2   | PPL3/intron                             |
| rs3851973        | 201732878| G            | 0.14| −0.59 | 1.79E-06 | 2   | PPL3/UTR-5 and CLK1/UTR-3              |
| rs111976464      | 201735042| C            | 0.14| −0.59 | 1.79E-06 | 2   | PPL3/UTR-5 and CLK1/UTR-3              |
| rs11892119       | 201736112| C            | 0.14| −0.59 | 1.79E-06 | 2   | PPL3/UTR-3                             |
| rs7562391        | 201736166| C            | 0.14| −0.59 | 1.79E-06 | 2   | PPL3/UTR-3                             |
| rs7560613        | 20200010 | C            | 0.21| −0.60 | 1.83E-06 | 2   | CFLAR/intron                            |
| rs6747253        | 201748415| A            | 0.15| −0.59 | 2.17E-06 | 2   | PPL3/intron                             |
| rs73043383       | 201968246| C            | 0.17| −0.59 | 2.19E-06 | 2   | CFLAR/UTR-5                             |
| rs7591472        | 201889751| C            | 0.17| −0.59 | 2.20E-06 | 2   | FAM126B/intron                          |
| rs10194347       | 201942480| A            | 0.17| −0.59 | 2.42E-06 | 2   | NDUFB3/intron                           |
| rs28405687       | 201906661| T            | 0.23| −0.59 | 2.52E-06 | 2   | FAM126B/intron                          |
| rs915650         | 37657526 | A            | 0.38| −0.59 | 2.54E-06 | 8   |                                         |
| rs7583529        | 201988238| A            | 0.21| −0.59 | 2.57E-06 | 2   | CFLAR/intron                            |
| rs6728771        | 201992407| A            | 0.21| −0.59 | 2.57E-06 | 2   | CFLAR/intron                            |
| rs6706980        | 201993688| A            | 0.21| −0.59 | 2.57E-06 | 2   | CFLAR/intron                            |
| rs58886660       | 201999283| A            | 0.21| −0.59 | 2.57E-06 | 2   | CFLAR/intron                            |
| rs28636431       | 201999530| C            | 0.21| −0.59 | 2.57E-06 | 2   | CFLAR/intron                            |
| rs7573256        | 202003170| G            | 0.21| −0.59 | 2.57E-06 | 2   | CFLAR/intron                            |
| rs113350756      | 202003767| G            | 0.21| −0.59 | 2.57E-06 | 2   | CFLAR/intron                            |
| rs10190751       | 202006096| A            | 0.21| −0.59 | 2.57E-06 | 2   | CFLAR/intron                            |
| rs56160734       | 202006800| A            | 0.21| −0.59 | 2.57E-06 | 2   | CFLAR/intron                            |
| rs4487072        | 202008298| T            | 0.21| −0.59 | 2.57E-06 | 2   | CFLAR/intron                            |
| rs1981726        | 202008700| A            | 0.21| −0.59 | 2.57E-06 | 2   | CFLAR/intron                            |
| rs7573259        | 202010626| T            | 0.21| −0.59 | 2.57E-06 | 2   | CFLAR/intron                            |
| rs13387186       | 20201268 | A            | 0.21| −0.59 | 2.57E-06 | 2   | CFLAR/intron                            |
| rs13413075       | 202012363| C            | 0.21| −0.59 | 2.57E-06 | 2   | CFLAR/intron                            |
| rs12104442       | 202013956| C            | 0.21| −0.59 | 2.57E-06 | 2   | CFLAR/intron                            |
Table 1 List of top 140 SNPs (p <0.00001) from GWAS analysis that were predictive of triptolide cytotoxicity in HapMap LCLs (Continued)

| rsID     | Chromosome | SNP | HapMap | p_value | Log10(p_value) | Haplotype Annotation |
|----------|------------|-----|--------|---------|-----------------|---------------------|
| rs12721505 | 202014238  | G   | 0.21   | −0.59   | 2.57E-06        | CFLAR/intron        |
| rs7571899  | 202015028  | G   | 0.21   | −0.59   | 2.57E-06        | CFLAR/intron        |
| rs7585993  | 202015114  | T   | 0.21   | −0.59   | 2.57E-06        | CFLAR/intron        |
| rs61289882 | 202015250  | A   | 0.21   | −0.59   | 2.57E-06        | CFLAR/intron        |
| rs68044560 | 202017080  | T   | 0.21   | −0.59   | 2.57E-06        | CFLAR/intron        |
| rs56863085 | 202017647  | C   | 0.21   | −0.59   | 2.57E-06        | CFLAR/intron        |
| rs719125   | 202017860  | T   | 0.21   | −0.59   | 2.57E-06        | CFLAR/intron        |
| rs56009967 | 202019094  | C   | 0.21   | −0.59   | 2.57E-06        | CFLAR/intron        |
| rs56161269 | 202019210  | A   | 0.21   | −0.59   | 2.57E-06        | CFLAR/intron        |
| rs2041766  | 202021495  | T   | 0.21   | −0.59   | 2.57E-06        | CFLAR/intron        |
| rs4482462  | 202021747  | C   | 0.21   | −0.59   | 2.57E-06        | CFLAR/intron        |
| rs75518195 | 60067404   | G   | 0.36   | 0.58    | 2.80E-06        | nearest gene (~150 kb down TECRL) |
| rs13384245 | 201760937  | G   | 0.17   | −0.58   | 2.89E-06        | NIF3L1/intron       |
| rs10204787 | 201762147  | A   | 0.17   | −0.58   | 2.89E-06        | NIF3L1/intron       |
| rs113388793| 201771341  | G   | 0.17   | −0.58   | 2.89E-06        | NIF3L1/UTR-3 and ORC2/UTR-3 |
| rs2307358  | 201785657  | T   | 0.17   | −0.58   | 2.89E-06        | ORC2/intron         |
| rs2307362  | 201785837  | A   | 0.17   | −0.58   | 2.89E-06        | ORC2/cds-synon      |
| rs4622700  | 201793113  | T   | 0.17   | −0.58   | 2.89E-06        | ORC2/Intron         |
| rs9288314  | 201794173  | T   | 0.17   | −0.58   | 2.89E-06        | ORC2/Intron         |
| rs10185727 | 201803711  | G   | 0.17   | −0.58   | 2.89E-06        | ORC2/intron         |
| rs13408964 | 201804972  | T   | 0.17   | −0.58   | 2.89E-06        | ORC2/Intron         |
| rs16836160 | 201813830  | G   | 0.17   | −0.58   | 2.89E-06        | ORC2/Intron         |
| rs13429609 | 201816257  | T   | 0.17   | −0.58   | 2.89E-06        | ORC2/Intron         |
| rs13392371 | 201816421  | A   | 0.17   | −0.58   | 2.89E-06        | ORC2/Intron         |
| rs16836477 | 201835457  | G   | 0.17   | −0.58   | 2.89E-06        | ORC2/Intron         |
| rs6719992  | 201871978  | G   | 0.17   | −0.58   | 2.89E-06        | FAM126B/intron      |
| rs13405753 | 201881677  | G   | 0.17   | −0.58   | 2.89E-06        | FAM126B/intron      |
| rs10197103 | 201885293  | T   | 0.17   | −0.58   | 2.89E-06        | FAM126B/intron      |
| rs13384791 | 201911164  | G   | 0.17   | −0.58   | 2.89E-06        | FAM126B/intron      |
| rs13417843 | 201913429  | G   | 0.17   | −0.58   | 2.89E-06        | FAM126B/intron      |
| rs10207746 | 201916418  | C   | 0.17   | −0.58   | 2.89E-06        | FAM126B/intron      |
| rs73043345 | 201920060  | G   | 0.17   | −0.58   | 2.89E-06        | FAM126B/intron      |
| rs13389349 | 201920618  | C   | 0.17   | −0.58   | 2.89E-06        | FAM126B/intron      |
| rs6737556  | 201924078  | T   | 0.17   | −0.58   | 2.89E-06        | FAM126B/intron      |
| rs7590522  | 201924788  | T   | 0.17   | −0.58   | 2.89E-06        | FAM126B/intron      |
| rs10194168 | 201942437  | T   | 0.17   | −0.58   | 2.89E-06        | FAM126B/intron      |
| rs10205971 | 201958201  | G   | 0.17   | −0.58   | 2.89E-06        | FAM126B/UTR-5 and CFLAR/UTR-5 |
| rs2110728  | 201965578  | A   | 0.17   | −0.58   | 2.89E-06        | CFLAR/UTR-5         |
| rs13421776 | 201760002  | G   | 0.19   | −0.58   | 3.33E-06        | NIF3L1/intron       |
| rs4381763  | 201776988  | G   | 0.19   | −0.58   | 3.33E-06        | ORC2/Intron         |
| rs10183261 | 201795767  | A   | 0.19   | −0.58   | 3.33E-06        | ORC2/Intron         |
| rs10205561 | 201809704  | T   | 0.19   | −0.58   | 3.33E-06        | ORC2/Intron         |
| rs2307357  | 201824092  | A   | 0.19   | −0.58   | 3.33E-06        | ORC2/Intron         |
| rs3087357  | 201828365  | G   | 0.19   | −0.58   | 3.33E-06        | ORC2/UTR-5          |
| SNP          | Chromosome | Reference Allele | Minor Allele | Minor Allele Minor Allele | OR Ratio | OR (95% CI) | p Value | Gene/Locus                        |
|-------------|------------|------------------|--------------|----------------------------|----------|-------------|---------|-----------------------------------|
| rs874358    | 201829602  | G                | 0.19         | −0.58                      | 3.33E-06 | 2 ORC2/UTR-5          |
| rs3900738   | 201863803  | A                | 0.19         | −0.58                      | 3.33E-06 | 2 FAM126B/intron     |
| rs16836568  | 201879948  | G                | 0.19         | −0.58                      | 3.33E-06 | 2 FAM126B/intron     |
| rs13416500  | 201771798  | A                | 0.18         | −0.58                      | 3.63E-06 | 2 NIF3L1/UTR-3 and ORC2/UTR-3 |
| rs13404596  | 201771801  | T                | 0.19         | −0.58                      | 3.63E-06 | 2 NIF3L1/UTR-3 and ORC2/UTR-3 |
| rs6757272   | 201728141  | A                | 0.35         | −0.58                      | 4.14E-06 | 2 CLK1/Intron         |
| rs10184098  | 202004190  | G                | 0.21         | −0.57                      | 4.45E-06 | 2 CFLAR/intron        |
| rs28447044  | 64903606   | T                | 0.46         | 0.57                       | 4.69E-06 | 4 nearest gene (250 kb down TECRL) |
| rs11660054  | 56603803   | G                | 0.26         | −0.57                      | 5.27E-06 | 18 ZNF532/intron     |
| rs34044649  | 15565593   | T                | 0.42         | −0.57                      | 5.59E-06 | 7                |
| c14.20107162 | 20107162  | C                | 0.24         | 0.73                       | 5.84E-06 | 14                |
| rs2950160   | 44260188   | G                | 0.31         | −0.57                      | 5.96E-06 | 8 CSMD1/intron       |
| c18.56609415 | 56609415  | T                | 0.24         | −0.57                      | 6.06E-06 | 18                |
| rs9854411   | 171921569  | C                | 0.16         | −0.57                      | 6.70E-06 | 3 FND3C3B/intron     |
| rs13412214  | 201774182  | T                | 0.23         | −0.56                      | 7.21E-06 | 2 NIF3L1/UTR-3 and ORC2/UTR-3 |
| rs13412430  | 201774355  | T                | 0.23         | −0.56                      | 7.21E-06 | 2 NIF3L1/UTR-3 and ORC2/UTR-3 |
| rs10172647  | 201778950  | A                | 0.23         | −0.56                      | 7.29E-06 | 2 ORC2/Intron        |
| rs3125719   | 29990966   | T                | 0.18         | −0.56                      | 7.30E-06 | 13 MTUS2/intron      |
| c2.201899549 | 201899549 | C                | 0.17         | −0.56                      | 7.35E-06 | 2                |
| rs6445044   | 171920569  | G                | 0.16         | −0.56                      | 7.48E-06 | 3 FND3C3B/intron     |
| rs6414541   | 171920637  | C                | 0.16         | −0.56                      | 7.48E-06 | 3 FND3C3B/intron     |
| rs3923825   | 171922127  | T                | 0.16         | −0.56                      | 7.48E-06 | 3 FND3C3B/intron     |
| rs3924140   | 171926314  | C                | 0.16         | −0.56                      | 7.48E-06 | 3 FND3C3B/intron     |
| rs4610256   | 171928021  | C                | 0.16         | −0.56                      | 7.48E-06 | 3 FND3C3B/intron     |
| rs6445045   | 171928400  | C                | 0.16         | −0.56                      | 7.48E-06 | 3 FND3C3B/intron     |
| rs9867872   | 171928985  | C                | 0.16         | −0.56                      | 7.48E-06 | 3 FND3C3B/intron     |
| rs9868872   | 171929530  | G                | 0.16         | −0.56                      | 7.48E-06 | 3 FND3C3B/intron     |
| rs4380442   | 171930381  | A                | 0.16         | −0.56                      | 7.48E-06 | 3 FND3C3B/intron     |
| rs6763764   | 171931389  | C                | 0.16         | −0.56                      | 7.48E-06 | 3 FND3C3B/intron     |
| rs6803181   | 171932256  | C                | 0.16         | −0.56                      | 7.48E-06 | 3 FND3C3B/intron     |
| rs6780871   | 171932606  | G                | 0.16         | −0.56                      | 7.48E-06 | 3 FND3C3B/intron     |
| rs6806070   | 171932935  | C                | 0.16         | −0.56                      | 7.48E-06 | 3 FND3C3B/intron     |
| rs7619745   | 171933571  | A                | 0.16         | −0.56                      | 7.48E-06 | 3 FND3C3B/intron     |
| rs2016325   | 66323500   | T                | 0.35         | 0.56                       | 7.68E-06 | 7                |
| rs6435066   | 201766203  | G                | 0.23         | −0.56                      | 8.00E-06 | 2 NIF3L1/Intron      |
| rs7917      | 201768238  | T                | 0.23         | −0.56                      | 8.00E-06 | 2 NIF3L1/missense    |
| rs11894842  | 201773545  | C                | 0.23         | −0.56                      | 8.00E-06 | 2 NIF3L1/UTR-3 and ORC2/UTR-3 |
| rs10167387  | 201808618  | C                | 0.23         | −0.56                      | 8.00E-06 | 2 ORC2/Intron        |
| rs68133847  | 201812251  | G                | 0.23         | −0.56                      | 8.00E-06 | 2 ORC2/Intron        |
| rs11892372  | 201819483  | A                | 0.23         | −0.56                      | 8.00E-06 | 2 ORC2/Intron        |
| rs3901120   | 201863530  | C                | 0.23         | −0.56                      | 8.00E-06 | 2 FAM126B/intron     |
| rs16836591  | 201894943  | T                | 0.23         | −0.56                      | 8.00E-06 | 2 FAM126B/intron     |
| rs10185136  | 201904301  | T                | 0.23         | −0.56                      | 8.00E-06 | 2 FAM126B/intron     |
| rs10197833  | 20190466   | C                | 0.23         | −0.56                      | 8.00E-06 | 2 FAM126B/intron     |
GPATCH1, and multiple SNPs on chr 5 and 14 with JAK1 expression. Multiple SNPs within CFLAR were associated with expression levels of MTVR1, PIP5K1B and C9orf19/GLRIP2.

Functional significance of CFLAR splicing SNP
We selected CFLAR for functional validation in our study on the basis of following observations; i) higher number of SNPs in CFLAR were associated with the triptolide cytotoxicity (Tables 1 and 2); ii) CFLAR SNP-mRNA pairs associated with triptolide cytotoxicity included three CFLAR mRNA probes additionally multiple SNPs within CFLAR were associated with each 3 mRNA probes. Majority of the significantly associated SNPs within CFLAR gene were intronic and occurred in high LD (Additional file 2: Figure S1). However, one CFLAR SNP, rs10190751 G > A, was present at the splice junction of exon 7 (Fig. 2a) and was significantly associated with triptolide cytotoxicity (Fig. 2b). We screened HapMap cell lines with AA, AG and GG genotype (3 cell lines in each genotype group) for long (CFLAR-L), short (CFLAR-S) and raji (CFLAR-R) forms of CFLAR splice variants. CFLAR-L form was present in all cell lines irrespective of the genotype whereas CFLAR-S form was only expressed in cell lines with at least one G allele (Fig. 3a). Real-time quantification of CFLAR splice variants showed significant association of AA genotype with low levels of CFLAR-L; complete absence of CFLAR-S and higher levels of CFLAR-R form (Fig. 3). Western blot analysis confirmed the association of C-FLIP protein isoform levels corresponding to rs10190751 genotype and CFLAR mRNA isoforms (Fig. 3c).

SiRNA mediated functional studies on CFLAR
We selected Panc-1 for further investigation for impact of siRNA mediated transient knockdown of CFLAR on cellular sensitivity to triptolide. We selected Panc-1 for further investigation for impact of siRNA mediated transient knockdown of CFLAR on cellular sensitivity to triptolide. Panc-1 was selected based on the literature evidence of efficient use of triptolide in pancreatic cancer at pre-clinical and clinical level [Ref] as well as CFLAR being reported as a therapeutic target for triptolide in Pancreatic cancer [ref]. Genotype of Panc-1 for rs10190751, was identified as GG, therefore all isoform of CFLAR expressed in this cell line and it makes this cell line a perfect model to do functional validation for different isoform. In a pancreatic cancer cell line, Panc-1, siRNA mediated knockdown resulted in significant reduction in the CFLAR-L, CFLAR-S and CFLAR-R isoforms and significant increase in sensitivity to, triptolide (Fig. 4a and b).

Over expression of CFLAR-long and short isoform
Since Panc-1 demonstrated change in chemo-sensitivity in siRNA mediated knockdown of CFLAR, we further overexpressed CFLAR-L and CFLAR-S forms in Panc-1 cell lines. Transient transfection of most abundant isoforms of CFLAR was done in Panc-1 cell line using pEFA-CFLAR-L and pEF6-V5-CFLAR-L plasmid for Long and Short form of CFLAR respectively. Compared to cells transfected with control plasmids the level of CFLAR protein isoforms were significantly increased (Fig. 4c). Over-expression CFLAR-L or CFLAR-S isoforms resulted in significant decrease in sensitivity for triptolide, (Fig. 4d).

Discussion
Triptolide is a diterpenoid triepoxide and has been used in traditional Chinese medicine for years. Poor water solubility and toxicity has limited its use in clinics, however recent advances focused on developing triptolide derivatives with better solubility such as MC002 [22], omtritolide [23], minnelide [10] etc. are showing promising advancements especially in pancreatic cancer. The anticancer activity of triptolide has been associated with its ability to inhibit various pro-proliferative or anti-apoptotic factors thereby inducing apoptosis [16]. Triptolide has been implicated in activation of both intrinsic and extrinsic apoptotic pathways by inducing caspase-8, −9 and 3 as well as by inducing cleavage of PARP [24, 25]. Given the fact that triptolide has a promising potential as a therapeutic agent, we designed this study to identify the
| Gene Symbol | Gene full name | Gene summary (Ref gene) | # of SNPs at p < 0.00001 |
|-------------|----------------|-------------------------|--------------------------|
| CFLAR       | Caspase 8 and FADD-like apoptosis regulator | The protein encoded by this gene is a regulator of apoptosis and is structurally similar to caspase-8. However, the encoded protein lacks caspase activity and appears to be itself cleaved into two peptides by caspase-8. Several transcript variants encoding different isoforms have been found for this gene, and partial evidence for several more variants exists | 45 |
| FAM126B     | Family With Sequence Similarity 126, Member B | This gene encodes a member of the cyclophilin family. Cyclophilins catalyze the cis-trans isomerization of peptidylprolyl imide bonds in oligopeptides. They have been proposed to act either as catalysts or as molecular chaperones in protein-folding events. Alternative splicing results in multiple transcript variants. PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides. | 22 |
| PPL3        | Peptidylprolyl isomerase 9cyclophilin)-like 3 | | 7 |
| ZNF532      | | | 2 |
| NDUFB3      | NADH dehydrogenase (ubiquinone0 1beta subcomplex,3, 12kD | This gene encodes an accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which is the first enzyme in the electron transport chain of mitochondria. This protein localizes to the inner membrane of the mitochondrion as a single-pass membrane protein. Mutations in this gene contribute to mitochondrial complex 1 deficiency | 3 |
| NIF3L1      | NIF3 NGG1 interacting factor 3-like 1(S. cerevisiae) | Functions as transcriptional corepressor | 11 |
| ORC2        | Origin recognition complex subunit 2 | The origin recognition complex (ORC) is a highly conserved six subunits protein complex essential for the initiation of the DNA replication in eukaryotic cells. Studies in yeast demonstrated that ORC binds specifically to origins of replication and serves as a platform for the assembly of additional initiation factors such as Cdc6 and Mcm proteins. The protein encoded by this gene is a subunit of the ORC complex. This protein forms a core complex with ORC3,−4, and −5. It also interacts with CDC45 and MCM10, which are proteins known to be important for the initiation of DNA replication. | 20 |
| CLK1        | CDC-like kinase 1 | This gene encodes a member of the CDC2-like (or LAMMER) family of dual specificity protein kinases. In the nucleus, the encoded protein phosphorylates serine/arginine-rich proteins involved in pre-mRNA processing, releasing them into the nucleoplasm. The choice of splice sites during pre-mRNA processing may be regulated by the concentration of transacting factors, including serine/arginine rich proteins. Therefore, the encoded protein may play an indirect role in governing splice site selection. Phosphorylates: SRSF1, SRSF3 and PTPN1. Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells and adenovirus E1A pre-mRNA | 1 |
| CSMD1       | CUB and Sushi multiple domains 1 | | 1 |
| FNDC3B      | fibronectin type III domain containing 3B | Binds microtubules. Together with MAPRE1 may target the microtubule depolymerase KIF2C to the plus-end of microtubules. May regulate the dynamics of microtubules at their growing distal tip | 15 |
| MTUS2       | microtubule associated tumor suppressor candidate 2 | | 1 |
| TPS3B2      | tumor protein p53 binding protein, 2 | This gene encodes a member of the ASPP (apoptosis-stimulating protein of p53) family of p53 interacting proteins. The protein contains four ankyrin repeats and an SH3 domain involved in protein-protein interactions. It is localized to the perinuclear region of the cytoplasm, and regulates apoptosis and cell growth through interactions with other regulatory molecules including members of the p53 family. It plays central role in regulation of apoptosis and cell growth via its interactions. Regulates TP53 by enhancing the DNA binding and transactivation function of TP53 on the promoters of proapoptotic genes in vivo. Inhibits the ability of APPBP1 to conjugate NEDD8 to CUL1, and thereby decreases APPBP1 ability to induce apoptosis. Impedes cell cycle progression at G2/M. Its apoptosis-stimulating activity is inhibited by its interaction with DDX42 | 1 |
genomic markers associated with triptolide cytotoxicity using LCLs from International HapMap project.

Our results identified a QTL on chromosome 2 consisting of several SNPs with significant association with triptolide IC50. This region on chromosome 2 included biologically interesting genes such as CLK1, PPL3, NIF3L1, CFLAR, NDUFB3, CASP10, CASP8 etc. (Tables 1 and 2) with important roles in apoptosis and cell cycle regulation pathways. Of particular interest was significant over-representation the top most significant SNPs in CFLAR gene (Caspase 8 and FADD like apoptosis regulator). CFLAR gene encodes for protein c-FLIP, best-known for its anti-apoptotic regulatory role by inhibiting TNF-alpha, FAS-L and TRAIL induced apoptosis [26]. Although most of the SNPs in CFLAR were intronic, one splicing SNP, rs10190751 (3' splice site of intron 6) was of particular interest [27]. CFLAR-protein, c-FILP exists in several isoforms due to alternate splicing, the most studied forms include long (C-FLIP-L) and short (C-FLIP-S) isoforms of 55 kD and 26 kD, respectively. CFLAR gene has 14 exons and inclusion or exclusion of intron 6 or exon 7 regulates the expression of long, or short or raji forms. CFLAR long form (CFLAR-L) skips exon 7 and is expressed as a full-length protein of 480 amino acids. CFLAR short form (CFLAR-S) includes exon 7 thereby changing the reading frame, creating an early stop codon, and hence a shorter isoform with 221 amino acids. C-FLIP-L is composed of two death effector domains (DEDs) at the amino terminus and a caspase homologous domain, structurally similar to caspase 8 and caspase 10 at carboxy terminus.

| Molecules in Network | Score | Focus | Top Functions |
|----------------------|-------|-------|---------------|
| Cellular Movement, Inflammatory Response, Cell-To-Cell Signaling and Interaction |
| Cell Death and Survival, Cellular Function and Maintenance, Molecular Transport |
| Cancer, Dermatological Diseases and Conditions, Developmental Disorder |
| Cellular Movement, Hematological System Development and Function, Immune Cell Trafficking |
| Carbohydrate Metabolism |

Table 3 Ingenuity pathway analysis tool mapped the genes identified in gene expression vs. cytotoxicity analysis to 5 networks

Table 4 Top probe and genes with expression levels in LCLs associated with Triptolide LC50

| Probe | chromosome | start | Stop | gene | Spearman correlation | P-value |
|-------|------------|-------|------|------|----------------------|---------|
| hmm21260-S | 12 | 3915842 | 3915878 | hmm21260 | -0.563 | 7.62E-06 |
| GL21389558-S | 12 | 128035309 | 128035358 | FLJ31978 | 0.554 | 1.16E-05 |
| Hs.390856-S | 1 | 111024040 | 111024089 | Hs.390856 | -0.553 | 1.18E-05 |
| Hs.469348-S | 2 | 96793632 | 96793677 | Hs.469348 | -0.531 | 3.04E-05 |
| GI37542736-S | 2 | 109782098 | 109782147 | LOC376934 | -0.53 | 3.20E-05 |
| Hs.128030-S | 5 | 55803569 | 55803618 | Hs.128030 | -0.522 | 4.33E-05 |
| GI37538743-S | 7 | 99411521 | 99411570 | LOC375744 | -0.518 | 5.18E-05 |
| GI40255097-S | 11 | 26541361 | 26541361 | MUC15 | -0.514 | 5.91E-05 |
| GI42660336-S | 14 | 89994713 | 89994762 | LOC400238 | -0.514 | 5.97E-05 |
| GI41352717-S | 12 | 112017575 | 112017602 | DTX1 | 0.509 | 7.33E-05 |
| hmm28068-S | 2 | 85500058 | 85500086 | hmm28068 | -0.509 | 7.37E-05 |
| GI4557282-I | 1 | 100093999 | 10009440 | AGL; GDE | -0.507 | 7.75E-05 |
| GI4504802-S | 1 | 65073667 | 65073716 | JAK1; JAK1A | 0.505 | 8.57E-05 |
| hmm35855-S | 9 | 116734605 | 116734654 | hmm35855 | -0.503 | 9.02E-05 |
| Gene expression (Gene symbol) | Gene description | Association with total # of SNPs (p < 0.0001) | Distribution of SNPs (Chr: number of SNPs) | Distribution of SNPs on gene (Bold indicates Maximum number of SNPs on Gene) |
|-------------------------------|------------------|-------------------------------------------|---------------------------------------------|--------------------------------------------------------------------------------|
| AGL (Chr1)                    | Amylo-Alpha-1, 6-Glucosidase, 4-Alpha-Glucanotransferase | 27 Chr2:1 / Chr4:2 / Chr6:2 / Chr16:22     | CHST5/ADAT1/GABARAPL2/LRP2/SCGN/TMEM231      |                                                                                |
| ASCL4 (Chr12)                 | Achaete-Scute Complex-Like 4                          | 24 Chr6:5 / Chr7:1 / Chr9:1 / Chr16:2 / Chr17:3 / Chr18:12 | MPG/ASXL3/ATP6V0A1/EEDP1/MPG/NAGLU          | PDZD2                                                                         |
| C2orf96/RUNX-IT1 (Chr21)      | RUNX1 Intron Transcript 1 (Non-Protein Coding)        | 3 Chr5:1 / Chr9:1 / Chr13:1                 |                                                                              |                                                                                |
| C9orf19/GLIPR2 (Chr9)         | Glioma Pathogenesis-Related Protein 2                 | 20 Chr12 / Chr26 / Chr5, 7, 11 and 14:1 each / Chr8:3 / Chr12:2 / Chr13:3 | ABBR1 / CAPN2 / CFLAR/ TP53BP2              |                                                                                |
| CRYG5 (Chr3)                  | crystallin, gamma 5                                    | 41 Chr1:30 Chr2 and Chr6; each Chr5:2 Chr8, 9 and 14:1 each | CAMTA1                                      |                                                                              |
| CTSK (Chr1)                   | Cathepsin X                                            | 19 Chr1:9 and 16:1 each/ Chr5:6/ Chr7, 9 and 17:2 each/ Chr14:4 each | CRISPLD2/FHAD1/IDE/PPTRD/RBFOX3/SNX6/SP4   |                                                                                |
| DTX1 (Chr12)                  | deltex homolog 1 (Drosophila)                          | 31 Chr6:5 / Chr9:1 / Chr14:2 / Chr21:23    | TIA1                                         |                                                                                |
| FOXO1 (Chr9)                  | Forkhead Box Protein Q1                                | 21 Chr1:6 / Chr3:10 / Chr5 and 6:1 each / Chr16:3 | FLYWCH1/GNG4/PARK2                         |                                                                                |
| GABARAPL1 (Chr12)             | GABA(A) Receptor-Associated Protein-Like 1             | 7 Chr2:5 / Chr6 and 14:1 each               | STRN3                                        |                                                                                |
| JAK1 (Chr1)                   | Janus Kinase 1                                          | 44 Chr1:8 / Chr2, 3, 6 and 10:2 each/ Chr4, 12 and 13:1 each / Chr5:12 / Chr8:3 / Chr14:10 | GPATCH2/ SLC6A15/ TFDP2                    |                                                                                |
| MAPKAPK2 (Chr1)               | Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 | 3 Chr1:12 / Chr5:1                         | ABBR1/ OPCML                                |                                                                                |
| MGC16186 (Chr10)              | DPY30 Domain Containing 2                              | 10 Chr4:4 / Chr7, 9 and 22:1 each / Chr10:3 | MANBA/ MYO18B                               |                                                                                |
| MGC16385 (Chr16)              | CENPB DNA-Binding Domains Containing 1                 | 18 Chr4:4 / Chr5:2 / Chr17 and 22:1 each / Chr14:10 | AGXT2L1/ GIP / ITPK1/ PDE6A                |                                                                                |
| MTND4 (mitochondrial)         | Mitochondrially Encoded NADH Dehydrogenase             | 16 Chr1:8 / Chr4, 6, 8, 9 and 14:1 each / Chr10:3 | GNG4/ GPATCH2/ SH2D4B                      |                                                                                |
| MTND5 (mitochondrial)         | Mitochondrially Encoded NADH Dehydrogenase 5           | 10 Chr9 and 10:1 / Chr14:8                  | PTGDR / SH2D4B                              |                                                                                |
| MTVR1 (Chr11)                 | Mammary Tumor Virus Receptor Homolog 1                 | 28 Chr2:23 / Chr6 and 10:1 each / Chr7:3   | NIF3L1/ C7orf42/ CFLAR/ FAM126B/NIF3L1/ ORC2 |                                                                                |
| MUC15 (Chr11)                 | Mucin 15, Cell Surface Associated                      | 16 Chr1:8 / Chr2:2 / Chr9, 15 and 21:1 each / Chr11:3 | CAPN2/CGNL1/TP53BP2                       |                                                                                |
| MXD4 (Chr9)                   | MAX dimerization protein 4                             | 13 Chr2:3 / Chr4, 5, 10 and 17:1 each / Chr9:2 / Chr16:4 | MPG/NPRL3/CDC46/KANK1/USP34               |                                                                                |
| NADSYN1 (Chr11)               | NAD Synthetase 1                                       | 38 Chr2:32 / Chr13:1 / Chr16:5             | ERBB4/ FHAD1/ GPATCH2                      |                                                                                |
| PIP5K1B (Chr9)                | Phosphatidylinositol 4-Phosphate 5-Kinase Type-1 Beta  | 75 Chr1:2 / Chr2:65 / Chr6 and 14:1 each / Chr7:4 / Chr13:2 | NIF3L1/ ABCC4/ CFLAR/ FAM126B/ GPATCH2/ NDUFB3/NIF3L1/ORC2/PPIL3/SMYD3/TSGA14 | LDLRAD3                                                                 |
| PDLX2 (Chr3)                  | podocanexin-like 2                                     | 44 Chr3 and 20:1 each / Chr11:39 / Chr11:3 | ABLIM2/ MANBA/ TTL1                        |                                                                                |
| ROPN1 (Chr3)                  | Rhophilin Associated Tail Protein 1                   | 7 Chr1:2 / Chr3:3 / Chr4 and 13:1          |                                                                              |                                                                                |
| SLC3SD2 (Chr9)                | Solute Carrier Family 35 Member D2                     | 18 Chr4 and 10:3 each / Chr5:10 / Chr13 and 22:1 each | n/a                                          |                                                                                |
| Gene Symbol | Gene Description | Chr Locations | Gene Interactions |
|-------------|------------------|---------------|-------------------|
| TDE1 (Chr20) | Tumor Differentially Expressed 1 | Chr 1:12 / Chr 2:10 and 1:4 each / Chr 3:6 / Chr 5:9 / Chr 8:7 / Chr 15:2 | FHAD1/PPCS/SMYD3/ZMYND12 |
| TWSG1 (Chr18) | Twisted Gastrulation Protein Homolog 1 | Chr 2:5 / Chr 6:3 | CLK1/FAM126B/ |
| VIAAT (Chr20) | Solute Carrier Family 32 Member 1 | Chr 6 and 10:4 each / Chr 12:1 / Chr 13:3 / Chr 14:41 / Chr 16:2 | SNX6/STRN3/RSU1 |
| VPS39 (Chr15) | Vacuolar Protein Sorting 39 | Chr 2, 3 and 5:3 each / Chr 4, 11, 13, 14 and 22:1 each | ACTN1/ARRB1/GRM7/SEZ6L |
| Total | | 648 | |

(Continued)
C-FLIP-S has two DEDs but lacks caspase homology domain. Presence of rs10190751 regulates the splicing event with rs10190751-A allele resulting in lack of expression of the short form (Fig. 4). In addition to these isoforms recently cFLIP-R forms has been identified in the Raji cells [27]. Due to intronic insertion; CFLAR-R isoform has a premature stop codon resulting in a protein with 212 amino acids and like the CFLAR-S isoform lacks caspase like domain.

Although the characterization of the functional differences of these isoforms is still ongoing, cell type specific pro-apoptotic role of CFLAR-L has been reported. CFLAR-L expression levels are considered critical factor in determining the balance between apoptotic and pro-survival signaling. The CFLAR-L has also been shown to play critical role in autophagy, necroptosis and apoptosis in T-lymphocytes with CFLAR-L deficiency triggering severe cell death upon stimulation [28]. In spite of its major role in regulating death receptor signaling, it has been shown to be involved in regulation of apoptosis by several other mechanism including; modulating the activity of ripoptosome [29] regulation of necroptosis by preventing caspase 8 activation [30–32], inhibiting autophagosome formation by interfering with conjugation of LC3 and in NFkB signaling with its ectopic expression resulting in NFkB activation [33–35].

Given the important role of CFLAR (CFLIP) as a key inhibitor of processing and activation of caspase 8; its prognostic and therapeutic relevance in AML [36] as well as in development of drug resistance [37] we designed this study to further explore the clinical significance of the CFLAR and its genetic variation especially the splicing SNP (regulating CFLAR-L and CFLAR-S forms) as biomarker of risk of disease as well as with development drug resistance. Our results of siRNA mediated knock down and overexpression of CFLAR in pancreatic cancer cell lines further provides evidence of its involvement in chemo-sensitivity to triptolide.

Gene expression levels of JAK1, AGL, and DTX1 genes, all involved in cell-to cell signaling (Additional file 4: Figure S3) has been associated with triptolide cytotoxicity analysis. JAK1, Janus Kinase 1 is involved in interferon-alpha/beta and -gamma signal transduction pathways and is a critical component of JAK/STAT
pathway; AGL is member of 4 alpha-glucanotransferase and is involved in glycogen degradation; DTX1, deltex homolog 1 is involved in NOTCH signaling pathway which is a critical for cell fate determination and has been implicated in several diseases as well as tumorigenesis [38]. In our integrative exploratory analysis we identified several biologically interesting gene-SNP-gene-expression pairs as TIAM1-DTX1, ASXL3: ASCL4, GPATCH2: JAK1, CAMPTA1-CRYGS, ERBB4-NADSYN1 etc.

In recent years there has been significant evidence suggesting triptolide mediated inhibition of ATPase activity of XPB, thereby influencing transcription as well as Nucleotide excision repair [39]. XPB, also known as ERCC3 is a subunit of transcription factor TFIIH. Triptolide has been shown to influence gene expression by globally reducing gene expression although to not to same extent for all genes by blocking transcription initiation [40, 41]. Antiproliferative effects of triptolide due to inhibition of XPB/TFIIH has also been shown to phenocopy JNK-dependent apoptosis phenotype in Dp53 deficient wing disc cells in Drosophila [42]. This global reduction of transcription caused by triptolide, correlates well with the phenotypes observed in tumour cells and in inflammation. If we take in account these evidences, and if the treatment with triptolide, reduce global transcription, cells with reduction of the CFLAR mRNA isoforms by the splicing SNP will be even more sensitive, since this gene may negatively modulates apoptosis. The KD and overexpression results using Panc-1 cells incubated with triptolide may also be explained in part by taking in account a reduction in global transcription caused by triptolide.

In conclusion, our results identified CFLAR as an important predictor of triptolide cytotoxicity. Splicing SNP-rs10190751 regulates production of CFLAR long and short isoforms, which are associated with triptolide cytotoxicity. The central role of anti-apoptotic protein c-FLIP (CFLAR product) in regulating death receptor signaling points to the fact that this splicing SNP might of importance to other chemotherapeutic agents. Up-
regulation of c-FLIP has been associated with poor clinical outcome and thus could be reliable prognostic factor for several types of cancer, however the significance of CFLAR genetic variation as predictor of therapeutic efficacy has not been explored so far, thus opening up opportunities for future studies.

Conclusions
Triptolide being an emerging drug, provides us a reason to do a genome wide association study to identify specific genetic polymorphism which may affect triptolide induced cytotoxicity. We observed significant association of triptolide IC50 with SNPs located in biological important genes from apoptotic pathway, such as CFLAR, PPIL3, caspase 8/10, NfKb and STAT6. CFLAR is an upstream regulator of apoptotic pathway. Due to its important position as a regulator of apoptosis, we validated its functional role in triptolide induced cytotoxicity in pancreatic cancer cell line. Our finding shows that CFLAR polymorphism plays important role in cancer cell death induced by triptolide. Further studies are needed to predict the therapeutic response in patients.

Availability of supporting data
Gene expression data is publically available from Gene Expression Omnibus under submission number series: GSE6536. Genotype data is available at HapMap.org-release 23 (www.HapMap.org).

Additional files

Additional file 1: Supplementary Notes.
Additional file 2: Figure S1. LD plot generated using Haploview for chromosome 2 region flanking CFLAR gene in CEU population.
**Competing interests**
The authors declare they have no competing interests.

**Authors contributions**
JKL, conceived the study design; LC, NB, TF and TMG performed the experiments; BLF and GDJ performed statistical analysis; All authors contributed to manuscript writing. All authors read and approved the final manuscript.

**Acknowledgements**
We are thankful to Professor Ingo Schmitz, (Helmholtz Center for Infection Research, Infektionenstr. Braunsweg, Germany) for providing CFLAR expression plasmids (pEF6-V5, pEF-Flag A, pEF6-V5-CFLAR-S and pEF-Flag A-CFLAR-L) and Dr. Gunda Georg for supplying triptolide. This work was supported by Minnesota State partnership funds; the Mayo Foundation and the US National Institute of Health (R21-GM86869; R21-CA182715; P30-CA168524; P20-GM103418; R01-CA132946; R21-CA155524).

**Author details**
1. Department of Pharmacotherapy and Translational Research, University of Florida, Gainesville, FL, USA. 2. Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. 3. Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN, USA. 4. Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS, USA.

Received: 25 September 2014 Accepted: 5 May 2015

**References**

1. Liu Z, Ma L, Zhou GB. The main anticancer bullets of the Chinese medicinal herb, thunder god vine. Molecules. 2011;16(6):5283–97.

2. Pan J. RNA polymerase - an important molecular target of triptolide in cancer cells. Cancer Lett. 2010;293(2):149–52.

3. Zhou GS, Hu Z, Fang HT, Zhang FX, Pan XF, Chen XQ, et al. Biologic activity of triptolide in t82/b1 acute myeloid leukemia cells. Leuk Res. 2011;35(2):214–8.

4. Chen Q, Lu Z, Jin Y, Wu Y, Pan J. Triptolide inhibits Jak2 transcription and induces apoptosis in human myeloproliferative disorder cells bearing Jak2617F through caspase-3-mediated cleavage of Mcl-1. Cancer Lett. 2010;291(2):246–55.

5. Miyata Y, Sato T, Ito A. Triptolide, a diterpenoid trioxide, induces antitumor proliferation via activation of c-Jun NH2-terminal kinase in cancer cells. Cancer Lett. 2010;292(1):140–52.

6. Liu Q, Chen T, Chen H, Zhang M, Li N, Lu Z, et al. Triptolide (PG-490) induces apoptosis of dendritic cells through sequential p38 MAP kinase phosphorylation and caspase 3 activation. Biochem Biophys Res Commun. 2004;319(3):890–6.

7. Antonoff MB, Chugh R, Skube SJ, Dudeja V, Borja-Cacho D, Clawson CD, et al. Role of p53 in the mitochondria-mediated cell death of neuroblastoma. J Surg Res. 2010;163(2):172–8.

8. Huang M, Zhang H, Liu T, Tian D, Gu L, Zhou M. Triptolide inhibits MDM2 and induces apoptosis in acute lymphoblastic leukemia cells through a p53-independent pathway. Mol Cancer Ther. 2013;12(2):184–94.

9. Zhao F, Chen Y, Zeng L, Li R, Zeng R, Wen L, et al. Role of tridolide in cell proliferation, cell cycle arrest, apoptosis and histone methylation in multiple myeloma U266 cells. Eur J Pharmacol. 2010b;646(1–3):1–11.

10. Chugh R, Sangwan V, Patil SP, Dudeja V, Dawra RK, Banerjee S, et al. Preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer. Sci Transl Med. 2012;4(156):156ra139.

11. Banerjee S, Thayannithy V, Sangwan V, Mackenzie TN, Saluja AK, Subramanian S. Minnelide reduces tumor burden in preclinical models of osteosarcoma. Cancer Lett. 2013;335(2):412–20.

12. International HapMap Project. www.hapmap.org.

13. Wheeler HE, Dolan ME. Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation. Pharmacogenomics. 2012;13(1):55–70.

14. Shukla SJ, Dolan ME. Use of CEPH and non-CEPH lymphoblast cell lines in pharmacogenetic studies. Pharmacogenomics. 2005;6(3):303–10.

15. Stark AL, Dolan ME. Lymphoblastoid cell lines in pharmacogenomics: how applicable are they to clinical outcomes? Pharmacogenomics. 2013;14(5):447–50.

16. Jiang J, F ridley BL, Feng Q, Abo RP, Britbin A, Batzler A, et al. Genome-wide association study for biomarker identification of Rapar nicyn and Everolimus using a lymphoblastoid cell line system. Front Genet. 2013;4:166.

17. Ritz C, SJC. Bioassy Analysis using R. Journal of Statistical Software 2005, 12(5):1–22.

18. Browning BL, Browning SR. A unified approach to genotype imputation and haplotype-phase inference for large data sets of tris and unrelated individuals. Am J Hum Genet. 2009;84(2):210–23.

19. Stranger BE, Forrest MS, Dunning M, Ingle CE, Beazley C, Thorne N, et al. Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science. 2007;315(5813):848–53.

20. Barbosa-Morais NL, Dunning MJ, Samarajiwa SA, Darot JF, Ritchie ME, Lynch Ag, et al. A re-annotation pipeline for Illumina BeadArrays: improving the interpretation of gene expression data. Nucleic Acids Res. 2010;38(s1):e17.

21. Huang RS, Duan S, Bleibel WK, Kistner EO, Zhang W, Clark TA, et al. A genome-wide approach to identify genetic variants that contribute to chemically-induced cytotoxicity. Proc Natl Acad Sci U S A. 2007;104(22):9768–63.

22. Zhang XM, Liu PX, Zhang YJ, Li CX, Li Y, Wang J, Zhou L, Zhang ZQ. Simultaneous determination of triptolide and its produg MC002 in dog blood by LC-MS/MS and its application in pharmacokinetic studies. Journal of ethnopharmacology 2013;150(1):131–7. 19. Kretin Ji, de Jonge MJ, Lamers CH, Eskens FA, van der Biesen D, van Doolm L, et al. Phase I dose-escalation study of 690003, a novel apoptosis inducer, in patients with advanced solid tumours. Eur J Cancer. 2009;45(10):1764–72.

23. Yang M, Huang J, Pan HZ, Jin J. Triptolide overcomes metsathemase resistance and enhanced PS-341-induced apoptosis via PI3K/Akt/NF-kappaB pathways in human multiple myeloma cells. Int J Mol Med. 2008;22(4):489–96.

24. Carter BZ, Mak DH, Schober WD, McQueen T, Harris D, Estrov Z, et al. Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood. 2006;108(2):630–7.

25. Miura K, Fujibuchi W, Unno M. Splice variants in apoptotic pathway. Exp Oncol. 2012;34(3):212–7.

26. Ueffling N, Singh KK, Christians A, Thorns C, Feller AC, Nagl F, et al. A single nucleotide polymorphism determines protein isomorph production of the human c-FLIP protein. Blood. 2009;114(3):572–9.

27. He MX, He YW. CFLAR/c-FLIPL: a star in the autophagy, apoptosis and necrosis interlacing. Autophagy. 2013;9(6):791–3.

28. Foekstistova M, Geserick P, Kellert B, Dimitrova DP, Langlais C, Hupe M, et al. cFLIPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol Cell. 2011;43(3):449–63.

29. Oberst A, Dillon CP, Weinrich R, McCormick DL, Fitzgerald P, Pop C, et al. Catalytic activity of the caspase-8-FIP3L complex inhibits RIPK3-dependent necrosis. Nature. 2011;471(7338):363–7.

30. Zhang H, Zhu X, McQuade T, Li J, Chan FK, Zhang J. Functional complementation between FADD and RIP1 in embryos and lymphocytes. Nature. 2011;471(7338):373–7.

31. Kaiser WJ, Upton JW, Long AB, Livingston-Rosanoff D, Daley-Bauer LP, Hakem R, et al. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature. 2011;471(7338):368–72.

32. Chaudhary PM, Eby MT, Jasmin A, Kumar A, Liu L, Hood L. Activation of the NF-kappaB pathway by caspase 8 and its homologs, Oncogene. 2000;19(39):4451–60.

33. Kataoka T, Tischopp J. N-terminal fragment of c-FLIP(L) processed by caspase-8 specifically interacts with TRAF2 and induces activation of the NF-kappaB pathways. Pharmacogenomics. 2005;6(3):303–10.

34. Kataoka T, Chugh R, Hellier N, Thorne M, Martinson F, Imler M, et al. The caspase-8 inhibitor FLIP promotes activation of the NF-kappaB and Erk signaling pathways. Current biology : CB. 2000;10(11):553–62.

35. McLornan D, Hay J, McLaughlin K, Holohan C, Burnett AK, Hills RK, et al. Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia. Br J Haematol. 2013;160(2):188–96.
37. Lee S, Yoon CY, Byun SS, Lee E, Lee SE. The role of c-FLIP in cisplatin resistance of human bladder cancer cells. J Urol. 2013;189(6):2327–34.

38. Ranganathan P, Weaver KL, Capobianco AJ. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer. 2011;11(5):338–51.

39. Chen F, Gao X, Shilatifard A. Stably paused genes revealed through inhibition of transcription initiation by the TFIIH inhibitor triptolide. Genes Dev. 2015;29(1):39–47.

40. Tee WW, Shen SS, Oksuz O, Narendra V, Reinberg D. Erk1/2 activity promotes chromatin features and RNAPII phosphorylation at developmental promoters in mouse ESCs. Cell. 2014;156(4):678–90.

41. Villicaña C, Cruz G, Zurita M. The genetic depletion or the triptolide inhibition of TFIIH in p53-deficient cells induces a JNK-dependent cell death in Drosophila. J Cell Sci. 2013;126(Pt 11):2502–15.

42. Titov DV, Gilman B, He QL, Bhat S, Low WK, Dang Y, et al. XPB, a subunit of TFIIH, is a target of the natural product triptolide. Nat Chem Biol. 2011;7(3):182–8.

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit